Clinical and Cytogenetic Data at Presentation and Relapse (Case 4)
| Case . | Sex/ Age . | Blood . | BM . | Immunophenotype . | Diagnosis (FAB) . | Treatment . | Response and Survival (mo) . | Cytogenetics . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC (×109/L) . | Pt (×109/L) . | Blasts (%) . | Cytology . | Blasts (%) . | Tissue . | Karyotype . | ||||||
| 1 | F/76 | 5.0 | 150 | 0 | Hypercellular, dysgranulopoiesis, dysmegakaryopoiesis | 24 | CD2+, CD5+, CD7+, CD13+, CD56+, CD33+, cyMPO+ | Myeloid/ NK cell leukemia | Intensive chemotherapy | CR1 (8+) | LN BM | 46, XX, t(4;12) (q12;p13) [20] 46, XX, t(4;12) (q12;p13) [9] / 46, XX [1] |
| 2 | M/70 | 36.0 | NA | 80 | Dry tap | NA | CD7+, CD13+, CD34+, HLA-DR+ | AML-M0 | Chemotherapy | Death at induction | BM | 46, XY, t(4;12) (q11;p13) [13] / 47, XY, t(4;12) (q11;p13) del(1) (p11p35) [18] |
| 3 | M/81 | 23.3 | 117 | 49 | Hypercellular, dysgranulopoiesis, dyserythropoiesis | 70 | CD4+, CD7+, CD13+, CD33+, CD34+, CD56+, HLA-DR+ | AML-M0 | Mild chemotherapy (supportive) | NR (3+) | BM | 46, XY, t(4;12) (q12;p13) [7] / 46, XY, t(4;12) (q11;p13), del(5) (q13q33), add(11)(p15) [13] |
| 4 | M/54 | 5.8 | 7 | 57 | Normocellular, dysgranulopoiesis, dysmegakaryopoiesis | 60 | CD7+, CD13+, CD33+, CD34+ | AML-M0 | Intensive chemotherapy | CR1 (26) | BM | 46, XY, t(4;12) (q11;p13) |
| NA | Relapse | 20 | Relapse | Chemotherapy and BM transplantation | CR2 (24+) | BM | 46, XY, t(4;12) (q11;p13) [3] / 46, XY [12] | |||||
| Case . | Sex/ Age . | Blood . | BM . | Immunophenotype . | Diagnosis (FAB) . | Treatment . | Response and Survival (mo) . | Cytogenetics . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC (×109/L) . | Pt (×109/L) . | Blasts (%) . | Cytology . | Blasts (%) . | Tissue . | Karyotype . | ||||||
| 1 | F/76 | 5.0 | 150 | 0 | Hypercellular, dysgranulopoiesis, dysmegakaryopoiesis | 24 | CD2+, CD5+, CD7+, CD13+, CD56+, CD33+, cyMPO+ | Myeloid/ NK cell leukemia | Intensive chemotherapy | CR1 (8+) | LN BM | 46, XX, t(4;12) (q12;p13) [20] 46, XX, t(4;12) (q12;p13) [9] / 46, XX [1] |
| 2 | M/70 | 36.0 | NA | 80 | Dry tap | NA | CD7+, CD13+, CD34+, HLA-DR+ | AML-M0 | Chemotherapy | Death at induction | BM | 46, XY, t(4;12) (q11;p13) [13] / 47, XY, t(4;12) (q11;p13) del(1) (p11p35) [18] |
| 3 | M/81 | 23.3 | 117 | 49 | Hypercellular, dysgranulopoiesis, dyserythropoiesis | 70 | CD4+, CD7+, CD13+, CD33+, CD34+, CD56+, HLA-DR+ | AML-M0 | Mild chemotherapy (supportive) | NR (3+) | BM | 46, XY, t(4;12) (q12;p13) [7] / 46, XY, t(4;12) (q11;p13), del(5) (q13q33), add(11)(p15) [13] |
| 4 | M/54 | 5.8 | 7 | 57 | Normocellular, dysgranulopoiesis, dysmegakaryopoiesis | 60 | CD7+, CD13+, CD33+, CD34+ | AML-M0 | Intensive chemotherapy | CR1 (26) | BM | 46, XY, t(4;12) (q11;p13) |
| NA | Relapse | 20 | Relapse | Chemotherapy and BM transplantation | CR2 (24+) | BM | 46, XY, t(4;12) (q11;p13) [3] / 46, XY [12] | |||||
Abbreviations: Pt, platelet; WBC, white blood cell count; BM, bone marrow; LN, lymph node; NA, not available; CR1/CR2, first (second) complete remission; NR, no remission.